RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole, is a
synthetic cannabinoid
Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids (THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic ...
drug sold under the names SR-19, BTM-4, or Eric-4 (later shortened to E-4), but originally, OBT-199.
Pharmacology
RCS-4 is a potent cannabinoid receptor agonist, with EC
50 values of 146 nM for human CB
1 receptors, and 46 nM for human CB
2 receptors.
All methoxyphenyl regioisomers, and ''N''-butyl homologues of RCS-4 and its regioisomers also display potent agonist activities at CB
1 and CB
2 receptors.
Legality
RCS-4 was banned in Sweden on 1 October 2010 as a hazardous good harmful to health, after being identified as an ingredient in "herbal"
synthetic cannabis
Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids (THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic ...
products.
It was outlawed in Denmark on 11 March 2011.
In August 2011, New Zealand added not only RCS-4 but also its 1-butyl homologue, and the 2-methoxybenzoyl isomers of both these compounds, to a temporary class drug schedule (i.e. equivalent to Class C but reviewed after 12 months, and with personal possession and use of small amounts decriminalised), which was newly created under the Misuse of Drugs Amendment Act 2011 passed a week earlier.
As of October 2015 RCS-4 is a controlled substance in China.
See also
*
AM-630
AM-630 (6-Iodopravadoline) is a drug that acts as a potent and selective inverse agonist for the cannabinoid receptor CB2, with a ''K''i of 32.1 nM at CB2 and 165x selectivity over CB1, at which it acted as a weak partial agonist. It is u ...
*
AM-679
*
RCS-8
*
Pravadoline
Pravadoline (WIN 48,098) is an antinflammatory and analgesic drug with an IC50 of 4.9 μM and a ''K''i of 2511 nM at CB1, related in structure to nonsteroidal anti-inflammatory drugs (NSAIDs) such as indometacin. It was developed in ...
(WIN 48,098)
*
Structural scheduling of synthetic cannabinoids To combat the illicit synthetic cannabinoid industry many jurisdictions have created a system to control these cannabinoids through their general (or Markush) structure as opposed to their specific identity. In this way new analogs are already cont ...
References
{{cannabinoids
Benzoylindoles
Designer drugs